SAT0734-HPR The effect of rheumatic diseases on work ability: a study of self-assessment of SF-36 in patients with smart system of disease management (SSDM). (15th June 2017)

• Record Type: Journal Article
• Authors: Song, H; Gu, J; Wu, H; Li, S; Zhao, Y; Sun, H; Huang, J; Li, X; Wu, R; Wu, B; Xiao, C; Qian, L; Xiao, F; Xiao, H; Wang, M; Jia, Y; Zhang, Z
• Is Part Of: Annals of the rheumatic diseases. Volume 76(2017)Supplement 2
• Page Start: 1516
• Page End: 1516
• Publication Date: 2017-06-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-eular.4990
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: A variety of rheumatic diseases can significantly affect the patient's quality of life and work ability. SF-36 is a commonly used tool to assess the quality of life and work ability in patients with chronic disease. In the past, most patients were guided by doctors/nurses to assess SF-36 in a paper form. At present, there is a lack of research on the quality of life in patients with rheumatic diseases by using new mobile tools in the real world. Objectives: To explore the effect to the life ability of rheumatic disease and the potential association between the disease activity and SF-36 in patients with rheumatoid arthritis (RA) using SSDM. Methods: SSDM is a new smart disease management mobile tool, which includes physicians' and patients' application system. After entering the results of SF-36 assessment by patients, all data can be synchronized automatically to the mobile terminal of authorized rheumatologist. According to the scores of SF-36 (<12.5, 12.5–50 and >50), the quality of life was divided into three levels: poor, moderate and good. Results: From June 2016 January 2017, data were extracted online from the mobile terminals of 839 adult patients (284 male and 555 female) in 62 hospitals across China. All patients performed self-assessment of SF-36 for a total of 1, 065 times. The mean age was 38.12±13.87 (18 to 81) years and the median disease duration was 20.60 (0 to 573) months. There are 25 kinds of rheumatic diseases involved, including RA (23%), ankylosing spondylitis (AS, 19%), systemic lupus erythematosus (SLE, 13%), osteoarthritis (OA, 11%), Sjogren syndrome (SS, 10%), polymyositis/dermatomyositis (PM/DM, 6%), mixed connective tissue disease (MCTD, 6%) and others (12%). The 8 items of SF-36 index were averaged between 49.07 (General Health perceptions, GH) to 74.12 (Physical Functioning, PF). The overall mean score of patients with different rheumatic diseases was higher than 50. However, there were 5 kinds of rheumatic diseases with average score of 5 items less than 50, including: MCTD, SS, PM/DM, AS and SLE in patients with GH score: 44.24, 44.60, 47.87, 47.93 and 49.16, PM/DM in patients with the Emotional Role functioning (RE): 47.52, Physical Role functioning (RP): 44.68 and AS patients with Reported Health Transition (HT): 49.64, respectively. In RA patients, 38% and 37% of patients reported that their ability to work were affected by disease and mood changes respectively. Bivariate correlation analysis showed that DAS28 was negatively correlated with the two item scores (RP and RE) of SF-36 index in RA patients, p<0.01. Conclusions: SSDM can be used to assess SF-36 in patients with rheumatic disease. The Quality of life scores in patients with MCTD, SS, PM/DM, AS, and SLE were more likely to be affected by rheumatic disease. The disease activity (DAS28) of RA patients was negatively correlated with the work ability (RP and RE of SF-36 score). Disclosure of Interest: None declared